Abstract

Drug-eluting stents (DES) have become the standard of care for the treatment of coronary artery disease. However, late stent thrombosis has emerged as a major concern, especially in ‘off-label’ use. Pathologic studies of patients dying from late DES thrombosis demonstrate delayed arterial healing, characterized by persistent fibrin deposition and poor endothelialization. In recent years, a novel prohealing device was developed that captures circulating endothelial progenitor cells (EPCs) by immobilized antihuman-CD34 antibody as a surface coating. EPCs have the ability to migrate to areas of vascular injury and aid in the regeneration of damaged and dysfunctional endothelium. Preclinical results of the EPC-capture stent have shown promise in accelerating endothelialization as compared with bare metal and DES. Clinically, the safety and efficacy of the EPC-capture stent has been proven in numerous clinical trials with low incidence of late stent thrombosis. In this article, we discuss the relevance of the ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.